Search Results for keywords:"Drug Enforcement Administration"

S&B Pharma LLC DBA Norac Pharma has submitted an application to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for further manufacturing and ANPP for producing other controlled substances. Public comments or objections to this application can be submitted electronically by March 28, 2025. The DEA will only approve import permits if the company's activities comply with specific federal regulations.

Navinta LLC has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. This registration is part of the process to gain approval for manufacturing these substances for validation purposes, which is a step required by the Food Administration before the substances can be distributed to their customers. The public, including current manufacturers of these substances, can submit comments or objections electronically by February 4, 2025. Comments should be submitted through the Federal eRulemaking Portal to ensure they are properly received.

The Drug Enforcement Administration (DEA) has announced that Sterling Wisconsin, LLC applied to register as a bulk manufacturer of certain controlled substances, specifically synthetic versions of Marihuana Extract, Marihuana, and Tetrahydrocannabinols. Interested parties can submit comments or objections electronically or request a hearing until May 27, 2025. The application was filed on January 30, 2025, and comments should be submitted via the Federal eRulemaking Portal as instructed.

Veranova, L.P. has applied to become a registered bulk manufacturer of specific controlled substances. The application has been submitted to the Drug Enforcement Administration (DEA) to support their manufacturing and analytical testing needs. Public comments or objections regarding this application can be submitted electronically through the Federal eRulemaking Portal until March 25, 2025. Individuals may also request a hearing about the application by the same date.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Dr. Matthew Okeke, who is based in Nevada. This order proposed revoking his DEA registration because he no longer has a valid state license or authority to handle controlled substances in Nevada. Dr. Okeke did not respond to the order, leading the DEA to proceed with final agency action to revoke his registration. The decision was signed by DEA Administrator Anne Milgram and is set to take effect on January 29, 2025.

Noramco Coventry, LLC has applied to the Drug Enforcement Administration to become an importer of certain controlled substances like raw opium and poppy straw concentrate. These substances will be used to manufacture bulk active pharmaceutical ingredients (APIs) that the company distributes. They will also import other substances for comparison with their own products to ensure quality before exporting their APIs to foreign markets. Public comments or objections to this application, including requests for a hearing, can be submitted until March 18, 2021.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), announced a notice for public commentary on its information collection request related to the National Forensics Laboratory Information System. This system gathers drug analysis data from non-federal labs to improve accuracy on drug information. The DEA is seeking approval from the Office of Management and Budget (OMB) for a three-year extension without changes to the existing collection, which involves responses from various agencies and businesses. Public comments on the burden and utility of this data collection are being accepted until March 3, 2025.

The Drug Enforcement Administration (DEA) is proposing a new rule to require that all applications and renewals for DEA registration be submitted online. This change will eliminate the current option to submit paper forms, making the process more efficient and cost-effective. The proposal is expected to save money for both the DEA and applicants by reducing errors and the need for corrections, while nearly all current applicants already use the internet for submissions. The rule change also aligns with federal efforts to streamline and modernize regulatory processes.

The Drug Enforcement Administration (DEA) decided to revoke the DEA Certificate of Registration for Dr. Willard J. Davis, a doctor in Texas, because he lost his state license to practice medicine, which means he can no longer handle controlled substances legally in Texas. The Texas Medical Board suspended Dr. Davis's medical license on May 16, 2024, and it remained suspended at the time of the decision. Since having a valid state medical license is necessary to maintain DEA registration for dispensing controlled substances, his registration was revoked, and any pending applications related to the registration were denied. This decision will be effective starting April 28, 2025.

Scottsdale Research Institute has applied to the Drug Enforcement Administration to become an importer of basic classes of controlled substances for clinical research. Specifically, they plan to bring in synthetic cannabidiol for use by Schedule I researchers. People interested in this application can submit comments or request a hearing by May 19, 2025. The application does not include permission for importing substances for commercial sale.